Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
Ziegler AG, Achenbach P, Weiß A, Berner R, Casteels K, Elding Larsson H, Haupt F, Hommel A, Jacobs A, Kordonouri O, Lundgren M, Ołtarzewski M, Pfirrmann M, Snape MD, Szypowska A, Todd JA, Vatish M, von dem Berge T, Winkler C, Bonifacio E; GPPAD-POInT Study Group.
Ziegler AG, et al.
Lancet. 2025 Nov 29;406(10519):2564-2576. doi: 10.1016/S0140-6736(25)01726-X. Epub 2025 Nov 11.
Lancet. 2025.
PMID: 41237794
Free article.
Clinical Trial.
Eligible infants aged 4-7 months were randomly assigned in a 1:1 ratio to receive insulin manufactured from human zinc-insulin crystals administered orally at a once-daily dose of 7.5 mg for 2 months, increasing to 22.5 mg for 2 months and 67.5 mg until age 3 years, or pla …
Eligible infants aged 4-7 months were randomly assigned in a 1:1 ratio to receive insulin manufactured from human zinc-insulin crysta …